Felix Mercer
Longevity Correspondent
Longevity maximalists tracking the cutting edge of lifespan science
Felix Mercer is PinnacleLife's longevity correspondent, tracking the frontier of lifespan science — senescence, NAD, rapamycin, biological-age testing and the people pushing it forward. Optimistic about the future, ruthless about the evidence.
Latest articles
Brain Maintenance: How an Active Mind and Body Map to a Younger Cognitive Age
Three converging analyses suggest that combining physical and mental engagement is linked to measurably younger brain and cognitive ages — with telomere length emerging as a partial mediator.
Heart-Healthy Habits Slow the Epigenetic Clock — But Not All Equally
A new Korean cohort study ranks which of the eight cardiovascular health pillars move the biological-age needle most — and the answer differs by sex.
PRP, Stem Cells, and Peptides: Where Regenerative Orthopedics Actually Has Evidence
A 2025 review of 160 studies grades four regenerative modalities for joint and tendon care. The signal is real — but uneven, and narrower than the marketing suggests.
Senotherapeutics 2.0: A Reishi Molecule, Rapamycin's Shadow, and the AI Hunt for Anti-Aging Drugs
A reishi-derived compound matched rapamycin in worms and rejuvenated aged mice. A parallel review maps how machine learning is industrializing the search for the next generation of senolytics.
Nocturia After 60: A Quiet Symptom That May Predict Frailty
New Berlin Aging Study II data suggest that waking at night to urinate isn't merely a nuisance — it may be an early, observable signal of functional decline in older adults.
The Sarcopenia Signal: Why Your Nerves, Not Just Your Muscles, Drive Age-Related Decline
A new systematic review reframes age-related strength loss as a problem of failing wires, not shrinking cables — and it changes what screening and training after 60 should look like.
Biological Age, Reimagined: What Bloodwork, mTOR, and New Biomarkers Can Actually Predict
A cluster of 2024–2025 papers is dragging biological-age science out of the speculative zone and into the realm of measurable prediction. The signal is real — but so are the caveats.
Measuring Age Itself: The Quiet Revolution in How We Quantify Getting Older
Two new papers — a framework for what a real aging biomarker must do, and a label-free way to read it inside mitochondria — suggest biological age is finally becoming measurable science.
The New Map of Aging: How Multiomics and Ribosome Biology Are Rewriting Longevity Science
A wave of 2025 research is pushing aging biology past single-pathway thinking — toward an integrated, system-level model that includes surprising new players like rRNA methylation and the slow failure of cellular recycling.
Epigenetic Clocks Move From Lab to Lifespan: How Biological Age Now Predicts Real Health
A new wave of studies is validating molecular age clocks as practical predictors of kidney, cardiovascular and functional health — nudging longevity science out of theory and toward the clinic.
Geroscience Goes Clinical: Targeting Aging Itself to Prevent Disease
A new wave of reviews argues that aging biology — not individual diseases — is medicine's highest-leverage target. Heart failure may be the proving ground.
GLP-1s Move Beyond Weight Loss: Parkinson's, Kidneys, Eyes, and the Brain
A phase 3 Parkinson's trial, a kidney meta-analysis, an ocular cohort and new mechanistic work suggest the GLP-1 class is becoming a multi-system intervention — with important caveats.